News
NWPHF
2.100
NaN%
--
Newron Pharmaceuticals’ Phase III Study on Evenamide: A Potential Game-Changer for Treatment-Resistant Schizophrenia
TipRanks · 10/27 21:32
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
Barchart · 10/03 00:46
Newron Pharmaceuticals Advances Evenamide Development with Positive H1 2025 Results
TipRanks · 09/16 05:36
Newron Pharmaceuticals Advances Evenamide Phase III Trials for Schizophrenia
TipRanks · 09/16 05:35
Weekly Report: what happened at NWPHF last week (0908-0912)?
Weekly Report · 09/15 11:07
Weekly Report: what happened at NWPHF last week (0901-0905)?
Weekly Report · 09/08 11:10
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
TipRanks · 09/05 05:33
Weekly Report: what happened at NWPHF last week (0825-0829)?
Weekly Report · 09/01 11:05
Weekly Report: what happened at NWPHF last week (0818-0822)?
Weekly Report · 08/25 11:15
Weekly Report: what happened at NWPHF last week (0811-0815)?
Weekly Report · 08/18 11:07
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
TipRanks · 08/12 05:34
Weekly Report: what happened at NWPHF last week (0804-0808)?
Weekly Report · 08/11 11:14
Newron Pharmaceuticals Unveils Promising Schizophrenia Treatment Findings
TipRanks · 08/11 05:34
Weekly Report: what happened at NWPHF last week (0721-0725)?
Weekly Report · 07/28 11:18
Weekly Report: what happened at NWPHF last week (0714-0718)?
Weekly Report · 07/21 11:08
Weekly Report: what happened at NWPHF last week (0707-0711)?
Weekly Report · 07/14 11:17
Weekly Report: what happened at NWPHF last week (0630-0704)?
Weekly Report · 07/07 11:08
Weekly Report: what happened at NWPHF last week (0623-0627)?
Weekly Report · 06/30 11:15
Weekly Report: what happened at NWPHF last week (0616-0620)?
Weekly Report · 06/23 11:07
More
Webull provides a variety of real-time NWPHF stock news. You can receive the latest news about Newron Phar through multiple platforms. This information may help you make smarter investment decisions.
About NWPHF
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.